A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206 · AndroMETa-CRC Phase 3Recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 990 (estimated)
- Start date
- 22 May 2026
- Primary completion
- May 2029 (estimated)
- Study completion
- 1 Mar 2030
- Last update posted
- 19 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Telisotuzumab adizutecan Drug
- Bevacizumab Drug
- Trifluridine/Tipiracil Drug
Conditions and primary outcome
- Colorectal Cancer
Primary outcome
Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR) (Up to Approximately 15 Months); Phase 3: Overall Survival (OS) (Up to Approximately 36 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedA randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 Oct 24
PubMed 42926107 (opens in a new tab)DOI 10.1016/j.annonc.2026.10.105 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07525206 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.